Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase IIα phosphorylation
AuthorConstantinou, Andreas I.
Vaughan, A. T. M.
Google Scholar check
MetadataShow full item record
To explore the program of cell differentiation in Friend murine erythroleukemia (MEL) cells, we used three clonal variants: phorbol 12- myristate 13-acetate (PMA)-hypersensitive TS-19-101, PMA-resistant TR19-9, and hexamethylene bis-acetamide (HMBA)- and PMA-resistant DS19/R1. After treating TS19-101 cells with HMBA, topoisomerase II (topo II) enzymatic activity was dramatically reduced, and cells became terminally differentiated. The initial reduction in activity was soon followed by reduced topo IIα phosphorylation, but only later did the protein level drop significantly. PMA, which completely blocked HMBA-induced differentiation in TS19-101 cells, increased the phosphorylation of topo IIα and restored the enzymatic activity to its original levels. Reduced topo II activity and phosphorylation were also evident in HMBA-treated TR19-9 cells. PMA failed to restore topo II activity and phosphorylation to their original levels in TR19-9 cells. Predictably, the topo II activity and phosphorylation of DS19/R1 cells showed little change in response to HMBA or PMA treatment. Structural changes in chromatin became evident in sensitive cells 24 h after HMBA treatment, suggesting that alterations in topo IIα phosphorylation may control cell differentiation by altering nuclear architecture.
Showing items related by title, author, creator and subject.
Cho, K. H.; Pezzuto, J. M.; Bolton, J. L.; Steele, V. E.; Kelloff, G. J.; Lee, S. K.; Constantinou, Andreas I. (2000)The present study was undertaken to determine if in vitro inhibition of one or both of the two most dominant mammalian DNA topoisomerases (topos) is common among chemopreventive agents. To determine if an agent was a topo ...
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
Constantinou, Andreas I.; Mehta, R.; Runyan, C.; Rao, K.; Vaughan, A.; Moon, R. (1995)Selected flavonoids were tested for their ability to inhibit the catalytic activity of DNA topoisomerase (topo) I and II. Myricetin, quercetin, fisetin, and morin were found to inhibit both enzymes, while phloretin, ...